BD (company)
Search results
CareFusion was created in 2009 as a spinoff of medical technology businesses from Cardinal Health. It began publicly trading on the New York Stock Exchange on September 1, 2009. [2] Cardinal's core business was drug distribution , a low-margin and low-risk, predictable business, with which the higher-margin, higher-risk medical technology ...
CareFusion proudly introduces the comprehensive line of high-quality, clinically-valued anesthesia delivery and patient monitor solutions from Vital Signs ® Vital Signs product categories include anesthesia consumables, airway access devices, patient monitoring, diagnostic cardiology (DCAR), perinatal monitoring and temperature management ...
Mar 17, 2015 · PR Newswire. FRANKLIN LAKES, N.J., March 17, 2015 / PRNewswire / -- Becton, Dickinson and Company (NYSE: BDX) ("BD") today announced that it completed its acquisition of CareFusion Corporation ("CareFusion") pursuant to the terms of its previously announced Agreement and Plan of Merger, dated October 5, 2014 (the "Merger Agreement").
People also ask
Will bd acquire CareFusion?
What does CareFusion do?
Does CareFusion own vital signs?
Where is CareFusion located?
CareFusion | 66,388 followers on LinkedIn. CareFusion, a BD company, is a global corporation serving the health care industry with products and services that help improve the cost and safety of...
BD is a leading provider of innovative solutions for medical discovery, diagnostics and care delivery. Learn about BD's history, values, ethics, segments and leadership.
Oct 5, 2014 · BD and CareFusion announced a definitive agreement to merge in October 2014, creating a global leader in medication management and patient safety solutions. The transaction was expected to generate significant value for shareholders, customers and employees, and to close in the first half of 2015.
Oct 6, 2014 · BD and CareFusion, two medical device companies, plan to merge in a $12.2 billion deal to expand their markets and products. The acquisition is one of several in the industry amid cost-cutting healthcare reforms and regulatory challenges.
